GL-PD
GL-PD
Globe Life Inc. 4.25% Junior SuIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $1.56B ▲ | $401.9M ▲ | $270.53M ▲ | 17.35% ▼ | $3.45 ▲ | $368.13M ▼ |
| Q4-2025 | $1.52B ▲ | $106.35M ▼ | $266M ▼ | 17.45% ▼ | $3.35 ▼ | $379.27M ▼ |
| Q3-2025 | $1.51B ▲ | $147.7M ▲ | $387.84M ▲ | 25.63% ▲ | $4.81 ▲ | $513.24M ▲ |
| Q2-2025 | $1.48B ▲ | $143.18M ▼ | $252.75M ▼ | 17.06% ▼ | $3.09 ▲ | $348.18M ▼ |
| Q1-2025 | $1.48B | $143.74M | $254.56M | 17.2% | $3.05 | $351.07M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $439M ▼ | $30.97B ▲ | $24.88B ▲ | $6.08B ▲ |
| Q4-2025 | $18.05B ▼ | $30.81B ▲ | $24.84B ▲ | $5.97B ▲ |
| Q3-2025 | $18.16B ▲ | $30.53B ▲ | $24.84B ▲ | $5.69B ▲ |
| Q2-2025 | $17.72B ▼ | $29.81B ▲ | $24.39B ▲ | $5.42B ▼ |
| Q1-2025 | $17.87B | $29.71B | $24.28B | $5.43B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $270.53M ▲ | $420.94M ▲ | $-281.26M ▼ | $-29.63M ▲ | $110.5M ▲ | $396.03M ▲ |
| Q4-2025 | $266.08M ▼ | $350.6M ▲ | $-265.84M ▼ | $-241.01M ▼ | $-158.01M ▼ | $330.1M ▲ |
| Q3-2025 | $387.84M ▲ | $305.98M ▼ | $-73.79M ▼ | $-171.79M ▲ | $63.59M ▲ | $208.69M ▼ |
| Q2-2025 | $252.75M ▼ | $307.93M ▼ | $-64.03M ▲ | $-230.78M ▼ | $6.85M ▼ | $294.99M ▼ |
| Q1-2025 | $254.56M | $431.89M | $-239.95M | $-124.46M | $66.94M | $420.14M |
Revenue by Products
| Product | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|
Health Segment | $380.00M ▲ | $390.00M ▲ | $390.00M ▲ | $420.00M ▲ |
Life Segment | $840.00M ▲ | $840.00M ▲ | $850.00M ▲ | $850.00M ▲ |
Q1 2026 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Globe Life Inc. 4.25% Junior Su's financial evolution and strategic trajectory over the past five years.
GL-PD’s underlying issuer, Globe Life, shows a combination of steady revenue growth, strong and stable profitability, and very robust free cash flow. The balance sheet is supported by growing retained earnings and improving liquidity, while the business itself benefits from a defensible niche, entrenched distribution channels, and simple, recurring-premium products. Together, these features contribute to a financial profile that has historically been resilient and supportive of its various capital instruments, including junior subordinated securities.
Key risks include a clear upward trend in leverage, with rising debt and interest costs, and aggressive capital returns to common shareholders that increase pressure on the balance sheet. Some data gaps and anomalies reduce transparency around the most recent year’s cost structure and certain balance-sheet items. Competitively, Globe Life faces threats from large insurers, digital-native entrants, and changing customer expectations, as well as the usual regulatory and economic risks that affect life insurers. For a junior instrument like GL-PD, these factors matter because they influence the issuer’s long-term capacity to meet all obligations across the capital structure.
Based on the information provided, Globe Life appears to be a mature, cash-generative insurer with a stable core franchise, gradually adapting to a more digital world while leaning more heavily on debt and buybacks to manage its capital structure. If it can maintain its strong cash generation, keep underwriting disciplined, and pace its leverage carefully, the overall financial profile should remain solid. The main variables to monitor over time are the balance between shareholder returns and balance-sheet strength, the trajectory of operating cash flows, and the company’s success in updating its distribution and technology to sustain its competitive edge.
About Globe Life Inc. 4.25% Junior Su
https://www.globelifeinsurance.comFounded in 1979 and based in McKinney, Texas, Globe Life Inc. (formerly Torchmark Corporation until its name change in August 2019) provides an array of life and supplemental health insurance products, alongside annuities, to lower-to-middle-income households across the United States through its various subsidiaries.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $1.56B ▲ | $401.9M ▲ | $270.53M ▲ | 17.35% ▼ | $3.45 ▲ | $368.13M ▼ |
| Q4-2025 | $1.52B ▲ | $106.35M ▼ | $266M ▼ | 17.45% ▼ | $3.35 ▼ | $379.27M ▼ |
| Q3-2025 | $1.51B ▲ | $147.7M ▲ | $387.84M ▲ | 25.63% ▲ | $4.81 ▲ | $513.24M ▲ |
| Q2-2025 | $1.48B ▲ | $143.18M ▼ | $252.75M ▼ | 17.06% ▼ | $3.09 ▲ | $348.18M ▼ |
| Q1-2025 | $1.48B | $143.74M | $254.56M | 17.2% | $3.05 | $351.07M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $439M ▼ | $30.97B ▲ | $24.88B ▲ | $6.08B ▲ |
| Q4-2025 | $18.05B ▼ | $30.81B ▲ | $24.84B ▲ | $5.97B ▲ |
| Q3-2025 | $18.16B ▲ | $30.53B ▲ | $24.84B ▲ | $5.69B ▲ |
| Q2-2025 | $17.72B ▼ | $29.81B ▲ | $24.39B ▲ | $5.42B ▼ |
| Q1-2025 | $17.87B | $29.71B | $24.28B | $5.43B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $270.53M ▲ | $420.94M ▲ | $-281.26M ▼ | $-29.63M ▲ | $110.5M ▲ | $396.03M ▲ |
| Q4-2025 | $266.08M ▼ | $350.6M ▲ | $-265.84M ▼ | $-241.01M ▼ | $-158.01M ▼ | $330.1M ▲ |
| Q3-2025 | $387.84M ▲ | $305.98M ▼ | $-73.79M ▼ | $-171.79M ▲ | $63.59M ▲ | $208.69M ▼ |
| Q2-2025 | $252.75M ▼ | $307.93M ▼ | $-64.03M ▲ | $-230.78M ▼ | $6.85M ▼ | $294.99M ▼ |
| Q1-2025 | $254.56M | $431.89M | $-239.95M | $-124.46M | $66.94M | $420.14M |
Revenue by Products
| Product | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|
Health Segment | $380.00M ▲ | $390.00M ▲ | $390.00M ▲ | $420.00M ▲ |
Life Segment | $840.00M ▲ | $840.00M ▲ | $850.00M ▲ | $850.00M ▲ |
Q1 2026 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Globe Life Inc. 4.25% Junior Su's financial evolution and strategic trajectory over the past five years.
GL-PD’s underlying issuer, Globe Life, shows a combination of steady revenue growth, strong and stable profitability, and very robust free cash flow. The balance sheet is supported by growing retained earnings and improving liquidity, while the business itself benefits from a defensible niche, entrenched distribution channels, and simple, recurring-premium products. Together, these features contribute to a financial profile that has historically been resilient and supportive of its various capital instruments, including junior subordinated securities.
Key risks include a clear upward trend in leverage, with rising debt and interest costs, and aggressive capital returns to common shareholders that increase pressure on the balance sheet. Some data gaps and anomalies reduce transparency around the most recent year’s cost structure and certain balance-sheet items. Competitively, Globe Life faces threats from large insurers, digital-native entrants, and changing customer expectations, as well as the usual regulatory and economic risks that affect life insurers. For a junior instrument like GL-PD, these factors matter because they influence the issuer’s long-term capacity to meet all obligations across the capital structure.
Based on the information provided, Globe Life appears to be a mature, cash-generative insurer with a stable core franchise, gradually adapting to a more digital world while leaning more heavily on debt and buybacks to manage its capital structure. If it can maintain its strong cash generation, keep underwriting disciplined, and pace its leverage carefully, the overall financial profile should remain solid. The main variables to monitor over time are the balance between shareholder returns and balance-sheet strength, the trajectory of operating cash flows, and the company’s success in updating its distribution and technology to sustain its competitive edge.

CEO
Frank Martin Svoboda
Compensation Summary
(Year 2025)
ETFs Holding This Stock
Summary
Showing Top 3 of 12
Ratings Snapshot
Rating : A-

